NMN raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-17 and is reviewed periodically as new material appears.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Identifies the atoms in the nucleotide |
| Molar mass | 334.22 g/mol | Calculated from the molecular formula |
| Appearance | White to off-white powder | Typical for purified solid material |
| Solubility | Water-soluble | Polar nucleotide; less soluble in nonpolar solvents |
| Common synonyms | Nicotinamide mononucleotide; beta-NMN | beta-NMN refers to the common anomeric form |
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Hero Certified Burgers is a quick service restaurant franchise chain that operates in Canada, with locations concentrated in Southern Ontario. The chain was founded in 2004 by John Lettieri, who opened the first store in Hazelton Lanes in Yorkville, Toronto, Ontario. Lettieri also owns the restaurant chain Lettieri café, based in Toronto. The company was the first Canadian franchise to focus on the provision of fast foods using food products from vendors that adhere to sustainable practices.
== Water and wastewater treatment == Microbubbles have been investigated as an aeration technology for water and wastewater treatment, where their long residence time, high specific surface area, and capacity to generate reactive oxygen species can improve gas-transfer efficiency and contaminant removal compared with conventional diffused aeration. Reviews of microbubble and nanobubble aeration have reported improvements in dissolved oxygen levels and biological oxygen demand removal in activated sludge processes when these technologies are applied in place of conventional aeration.
=== Evolutionary history === Genetic analysis of mitochondrial DNA shows the Komodo dragon to be the closest relative (sister taxon) of the Australian lace monitor (V. varius), with their common ancestor diverging from a lineage that gave rise to the crocodile monitor (Varanus salvadorii) of New Guinea. A 2021 study showed that during the late Miocene, the ancestors of Komodo dragons had hybridized with the common ancestor of Australian sand monitors (V. spenceri, V. gouldii, V. rosenbergi and V. panoptes). Fossils from across Queensland demonstrate that the Komodo dragon was once present in Australia, with fossils spanning from the Early Pliocene (~3.8 million years ago) to the Middle Pleistocene, with the youngest confirmed records of the species in Australia dating to at latest 330,000 years ago. In Australia, it coexisted with the even larger monitor species Varanus priscus also known as megalania, the largest terrestrial lizard ever. The oldest records of the Komodo dragon on Flores date to around 1.4 million years ago, during the Early Pleistocene. Additionally, Pleistocene fossils of Varanus found in Java and Timor may belong to the Komodo dragon.
One of the largest traditional markets in Taiwan, the Jianguo Market in Taichung, was torn down and replaced by a new facility in 2016. The new facilities provided better hygiene, disability accessibility, and refrigeration, but the relocation was initially met with hesitation from the local vendors before a grassroots outreach campaign led to greater acceptance.
Sources: en.wikipedia.org
Malnutrition-related diabetes, also termed Type 5 diabetes, involves decreased insulin production, similar to Type 1 diabetes, but is primarily related to malnutrition rather than autoimmune damage of pancreas beta cells. Unlike in Type 1 diabetes, patients with Type 5 diabetes do not develop ketonuria or ketosis. The ICD-10 (1992) diagnostic entity, malnutrition-related diabetes mellitus (ICD-10 code E12), was previously deprecated by the World Health Organization (WHO) when the current taxonomy was introduced in 1999.
=== REM sleep behavior disorder === Melatonin is a safer alternative than clonazepam in the treatment of REM sleep behavior disorder – a condition associated with the synucleinopathies like Parkinson's disease and dementia with Lewy bodies. However, clonazepam may be more effective. In any case, the quality of evidence for both treatments is very low and it is unclear whether either is definitely effective.
Alcohol (ethanol/ethyl alcohol) – GABAA receptor positive allosteric modulator Alkyl nitrites (poppers) (e.g., amyl nitrite) – nitric oxide donors, vasodilators, muscle relaxants, inhalants Cannabinoids (e.g., THC, cannabis, synthetic cannabinoids) – cannabinoid CB1 receptor agonists Dissociative hallucinogens (e.g., ketamine, methoxetamine, phencyclidine (PCP)) – ionotropic glutamate NMDA receptor antagonists Entactogens (empathogens) (e.g., MDMA (ecstasy), mephedrone, 6-APB, borax combo) – serotonin–norepinephrine–dopamine releasing agents (SNDRAs), other actions γ-Hydroxybutyric acid (GHB; oxybate) and prodrugs (e.g., GBL, 1,4-BD) – GABAB and GHB receptor agonists Phosphodiesterase PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil) Psychostimulants (stimulants) (e.g., amphetamine, methamphetamine, cocaine, mephedrone (4-MMC), metaphedrone (3-MMC), MDPV) – norepinephrine–dopamine releasing agents (NDRAs) and/or norepinephrine–dopamine reuptake inhibitors (NDRIs) Serotonergic psychedelics (e.g., 2C-B, 5-MeO-DiPT, 5-MeO-MiPT) – serotonin 5-HT2A receptor agonists
== Clinical trial == The National Institutes of Health announced on 27 February 2015 the commencement of a randomized controlled trial of ZMapp to be conducted in Liberia and the United States. From March 2015 through November 2015, 72 individuals infected with the Ebola virus were enrolled in the trial; investigators stopped enrolling new subjects in January 2016, having failed to reach its enrollment goal of 200 due to the waning of the Ebola outbreak. As a result, although a 40% lower risk of death was calculated for those who received ZMapp, the difference was not statistically significant and ultimately it could not be determined whether the use of ZMapp was superior to the optimized standard of care alone. However, ZMapp was found to be safe and well tolerated.
=== Recipient's selection of donors === Sperm banks make information available about the sperm donors whose donations they hold to enable customers to select the donor whose sperm they wish to use. This information is often available by way of an online catalog. Subscription fees to be able to view the sperm donor through California Cryobank, for example, start at $145. Information made available by a sperm bank will usually include the race, height, weight, blood group, health and eye color of the donor. Sometimes information about the donor's age, family history and educational achievements will also be given. Some sperm banks make a 'personal profile' of a donor available and occasionally more information may be purchased about a donor, either in the form of a DVD or in written form. Catalogs usually state whether samples supplied by a particular donor have already given rise to pregnancies, but this is not necessarily a guide to the fecundity of the sperm since a donor may not have been in the program long enough for any pregnancies to have been recorded. The donor's educational qualification is also taken into account when choosing a donor.
Sources: en.wikipedia.org
===== MeSH D08.811.520.650 – phosphorus-oxygen lyases (EC 4.6) ===== MeSH D08.811.520.650.200 – adenylate cyclase MeSH D08.811.520.650.200.040 – adenylate cyclase toxin MeSH D08.811.520.650.600 – guanylate cyclase MeSH D08.811.520.650.600.500 – receptors, guanylate cyclase-coupled MeSH D08.811.520.650.600.500.500 – receptors, atrial natriuretic factor MeSH D08.811.520.650.800 – phosphatidylinositol diacylglycerol-lyase
=== Bridging projects === The enolase superfamily contains evolutionarily related enzymes with a (β/α)7β‑barrel (TIM‑barrel) fold which primarily catalyze metal-assisted epimerization/racemization or β-elimination of carboxylate substrates. The Haloacid dehydrogenase superfamily contains evolutionarily related enzymes with a Rossmanoid α/β fold with an inserted "cap" region which primarily catalyze metal-assisted nucleophilic catalysis, most frequently resulting in phosphoryl group transfer. The isoprenoid synthase (I) superfamily contains evolutionarily related enzymes with a mostly all α-helical fold and primarily catalyze trans-prenyl transfer reactions to form elongated or cyclized isoprene products. The Anaerobic Enzymology bridging project will explore radical-dependent enzymology, which allows the execution of unusual chemical transformations via an iron-sulfur cluster cleaving S-Adenosyl methionine (SAM) and producing a radical intermediate, or alternatively, abstraction of a hydrogen from glycine producing a glycyl radical. The superfamilies containing these enzymes are largely unexplored and thus, ripe with the potential for functional discoveries. The acquisition of an anaerobic protein production pipeline coupled with the installation of a Biosafety Level 2 anaerobic chamber for culturing human gut microbes has readied the EFI to pursue anaerobic enzymology.
As treasurer, Kennedy sought to refinance portions of Louisiana's debt from Hurricanes Katrina and Rita as interest rates decreased. He worked with the state legislature and several governors' offices to negotiate each refinancing. In 2004, Kennedy told the state legislature that he could save more than $1.4 billion by refinancing the state's debt. He noted that he had sent Governor Kathleen Blanco several letters about refinancing that went unanswered. In 2011, Kennedy announced that Lafayette and Livingston Parishes had saved $11 million by refinancing. By 2013, Kennedy said he had "refinanced virtually all of the state's debt". In 2014, Kennedy worked to refinance $229 million in bond debt. The project faced delays because of a disagreement with Governor Bobby Jindal's office over accounting practices. Jindal's team claimed Kennedy was "unnecessarily holding up" progress on many construction projects, but Kennedy maintained that Jindal's accounting practices potentially violated federal anti-fraud laws. The two sides eventually compromised and the deal moved ahead, saving Louisiana $12 million. By the end of 2014, Kennedy had saved Louisiana a total of more than $600 million by refinancing debt. In 2015, Kennedy saved Louisiana $109 million over 26 years by refinancing a $649 million loan that funded a highway project.
=== Acute Metabolic Decompensation === When Leucine plasma levels elevate due to not following the strict MSUD diets, infection, or physiological stress this may induce acute metabolic decompensation. Individuals with lower residual BCKAD activity have increased risk. Typically Leucine levels >380 mmol/L will lead to metabolic decompensation. The goal in treating acute decompensation is to stop protein breakdown and increase protein synthesis. When an individual is facing acute metabolic decompensation it is important to remove or correct the stressor that is causing physiologic decompensation. During decompensation, the individual must be still receiving the proper amount of calories, insulin, free amino acids, isoleucine, and valine to help promote protein synthesis.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.
NMN is a direct precursor to NAD+ in the salvage pathway. The enzyme NMNAT converts NMN into NAD+ by adding an adenine nucleotide group. This relationship is why NMN is studied in the context of NAD+ decline.
Yes, NMN is produced naturally in cells as part of NAD+ recycling. It also appears in small and variable amounts in some foods. Its natural presence does not by itself establish that supplemental NMN has clinical benefits.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It consists of nicotinamide, ribose, and phosphate groups.